{"id":52206,"date":"2024-08-13T16:11:32","date_gmt":"2024-08-13T14:11:32","guid":{"rendered":"https:\/\/www.fyb.de\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/"},"modified":"2024-08-18T16:12:05","modified_gmt":"2024-08-18T14:12:05","slug":"aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/","title":{"rendered":"Aachen-based PL BioScience closes Series A for 7.8 million euros"},"content":{"rendered":"

Aachen, August 9, 2024 \u2014 PL BioSci\u00adence GmbH, pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing.
\nThe finan\u00adcing round attrac\u00adted signi\u00adfi\u00adcant invest\u00adments from AVANT BIO (New York), LePure Biotech (Shang\u00adhai), b.value AG (Dort\u00admund) and better ventures (Munich).
\nThe four part\u00adners contri\u00adbute their expe\u00adri\u00adence in deep tech, life scien\u00adces and health tech.
\nThe consor\u00adtium joins a group of exis\u00adting inves\u00adtors led by Bright\u00adlands Venture Part\u00adners (Geleen) and Tech\u00adVi\u00adsion Fonds (Aachen), who have once again pled\u00adged their support for the Aachen-based biotech company\u2019s mission.
\nPL BioSci\u00aden\u00adce\u2019s inno\u00adva\u00adtive Human Plate\u00adlet Lysate (HPL) tech\u00adno\u00adlogy enables breakth\u00adrough deve\u00adlo\u00adp\u00adments in cell therapy.
\n\u201cWe look forward to conti\u00adnuing our support for PL BioSci\u00adence and its outstan\u00adding HPL products in the coming years toge\u00adther with this great consor\u00adtium of inves\u00adtors,\u201d says Bern\u00adhard Kugel, Mana\u00adging Part\u00adner of the Tech\u00adVi\u00adsion Fund.
\nDr. Luc Starm\u00adans, Part\u00adner at Bright\u00adlands Venture Part\u00adners, also expres\u00adses his contin\u00adued commit\u00adment: \u201cWe warmly congra\u00adtu\u00adlate the team and welcome our new part\u00adners on this exci\u00adting jour\u00adney. Toge\u00adther, we look forward to buil\u00adding on PL BioSci\u00aden\u00adce\u2019s ground\u00adbrea\u00adking work to advance effec\u00adtive cell thera\u00adpies that will bring trans\u00adfor\u00adma\u00adtive bene\u00adfits to both pati\u00adents and the planet.\u201d Pionee\u00adring cell culture tech\u00adno\u00adlogy from Aachen<\/strong>
\n HPL is deri\u00adved from dona\u00adted blood that is no longer suita\u00adble for trans\u00adfu\u00adsion and offers a sustainable and effec\u00adtive alter\u00adna\u00adtive to animal-deri\u00adved cell culture media. Conven\u00adtio\u00adnal methods often use fetal calf serum (TCS), which is obtai\u00adned from the blood of calf fetu\u00adses. With HPL, a more seam\u00adless trans\u00adfera\u00adbi\u00adlity of rese\u00adarch results to humans is possi\u00adble. The tech\u00adno\u00adlogy ensu\u00adres relia\u00adble results in labo\u00adra\u00adto\u00adries world\u00adwide, paving the way for major advan\u00adces in rege\u00adne\u00adra\u00adtive medi\u00adcine. \u201cPL BioSci\u00aden\u00adce\u2019s Elarem plat\u00adform uniquely meets the needs of rese\u00adar\u00adchers by provi\u00adding human plate\u00adlet-based cell culture media along the entire rese\u00adarch chain,\u201d says Rein\u00adhard Vogt, Part\u00adner at AVANT BIO, who will join PL BioSci\u00aden\u00adce\u2019s Advi\u00adsory Board upon comple\u00adtion. \u201cWe are exci\u00adted to support PL BioSci\u00adence as it enters a new phase of commer\u00adcial expan\u00adsion, both with working capi\u00adtal and with our team\u2019s deca\u00addes of expe\u00adri\u00adence in cell culture media.\u201d
\nRege\u00adne\u00adra\u00adtive treat\u00adments based on cell thera\u00adpies <\/strong> The company\u2019s exten\u00adsive custo\u00admer base, which includes leading life science and biome\u00addi\u00adcal compa\u00adnies, rese\u00adarch insti\u00adtu\u00adti\u00adons and univer\u00adsity hospi\u00adtals, relies on PL BioSci\u00aden\u00adce\u2019s HPL to deve\u00adlop breakth\u00adrough cellu\u00adlar thera\u00adpies. These cell thera\u00adpies rely on highly safe and effec\u00adtive growth media to improve the treat\u00adment opti\u00adons for auto\u00adim\u00admune dise\u00ada\u00adses such as type 1 diabe\u00adtes melli\u00adtus or the possi\u00adbi\u00adli\u00adties in wound heal\u00ading. Tina Drei\u00admann, foun\u00adder and Mana\u00adging Direc\u00adtor of better ventures<\/strong>, summa\u00adri\u00adzes the company\u2019s mission: \u201cWe are exci\u00adted to support PL BioSci\u00adence in revo\u00adlu\u00adtio\u00adni\u00adzing rege\u00adne\u00adra\u00adtive medi\u00adcine with their inno\u00adva\u00adtive HPL tech\u00adno\u00adlogy. With a strong team, a proven market fit and a stra\u00adte\u00adgic patent port\u00adfo\u00adlio, PL BioSci\u00adence stands out as an excep\u00adtio\u00adnal invest\u00adment in the biome\u00addi\u00adcal space.\u201d Massive growth in global demand for cell culture media <\/strong>Dr. Hatim Hemeda, co-foun\u00adder and CEO of PL BioScience<\/strong>
\nis obser\u00adving the growing demand for cell culture media that meet the high requi\u00adre\u00adments of clini\u00adcal studies: \u201cThe incre\u00adasing number of clini\u00adcal studies, espe\u00adci\u00adally with stem cells, is opening up promi\u00adsing approa\u00adches. This increase is driving the estab\u00adlish\u00adment of produc\u00adtion faci\u00adli\u00adties and the further deve\u00adlo\u00adp\u00adment of regu\u00adla\u00adtory frame\u00adworks, which is leading to a signi\u00adfi\u00adcant rise in global demand for cell culture media.\u201d The global market for stem cell therapy, for exam\u00adple, is fore\u00adcast to grow from USD 15 billion in 2024 to USD 63 billion in 2031, more than quadru\u00adpling in terms of market volume. (Source: Global Stem Cell Therapy Market, Coher\u00adent Market Insights, 2024.) This trend is clearly visi\u00adble not only in Europe and the USA, but also in China, where demand for HPL is growing rapidly. \u201cChina curr\u00adently relies almost exclu\u00adsi\u00advely on impor\u00adted media for the culti\u00adva\u00adtion of stem cells and T cells. With the advance\u00adment of rege\u00adne\u00adra\u00adtive medi\u00adcine, the market poten\u00adtial for HPL culture media in China is huge,\u201d said Yu Chen, CFO at LePure Biotech.
\nStra\u00adte\u00adgic part\u00adner\u00adship drives geogra\u00adphic expan\u00adsion <\/strong>Chris\u00adtian Wilkes, co-foun\u00adder and CFO of PL BioScience<\/strong>
\nempha\u00adsi\u00adzes the stra\u00adte\u00adgic importance of the inter\u00adna\u00adtio\u00adnal part\u00adner\u00adships: \u201cBy offe\u00adring high-quality, animal-free growth media, we have been able to build a solid repu\u00adta\u00adtion both locally and globally. The invol\u00advement of renow\u00adned invest\u00adment compa\u00adnies from Europe, the US and China acce\u00adle\u00adra\u00adtes our global growth stra\u00adtegy and streng\u00adthens our presence in these emer\u00adging geogra\u00adphic markets.\u201d Peter Kallien, Mana\u00adging Part\u00adner and foun\u00adder of b.value AG, high\u00adlights the poten\u00adtial of the Aachen-based company: \u201cPL BioSci\u00adence is perfectly posi\u00adtio\u00adned as its HPL meets the high demands of clini\u00adcal cell culture while being scalable to serve the growing rege\u00adne\u00adra\u00adtive medi\u00adcine market. We are proud to support a team that not only has the exper\u00adtise, but also the passion to make a real difference.\u201d <\/p>\n","protected":false},"excerpt":{"rendered":"

Aachen, August 9, 2024 \u2014 PL BioSci\u00adence GmbH, pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A finan\u00adcing. The finan\u00adcing round attrac\u00adted signi\u00adfi\u00adcant invest\u00adments from AVANT BIO (New York), LePure Biotech (Shang\u00adhai), b.value AG (Dort\u00admund) and better ventures (Munich). The four part\u00adners contri\u00adbute their expe\u00adri\u00adence in deep tech, [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":52204,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-52206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en"],"yoast_head":"\nAachen-based PL BioScience closes Series A for 7.8 million euros - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"Aachen-based PL BioScience GmbH, a pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing round. The financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aachen-based PL BioScience closes Series A for 7.8 million euros - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Aachen-based PL BioScience GmbH, a pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing round. The financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-13T14:11:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-18T14:12:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Aachen-based PL BioScience closes Series A for 7.8 million euros\",\"datePublished\":\"2024-08-13T14:11:32+00:00\",\"dateModified\":\"2024-08-18T14:12:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\"},\"wordCount\":790,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Investors\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\",\"url\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\",\"name\":\"Aachen-based PL BioScience closes Series A for 7.8 million euros - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg\",\"datePublished\":\"2024-08-13T14:11:32+00:00\",\"dateModified\":\"2024-08-18T14:12:05+00:00\",\"description\":\"Aachen-based PL BioScience GmbH, a pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing round. The financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg\",\"width\":1500,\"height\":1000,\"caption\":\"Tina Dreimann, Gr\u00fcnderin und Gesch\u00e4ftsf\u00fchrerin von better ventures \u00a9 better ventures\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aachen-based PL BioScience closes Series A for 7.8 million euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aachen-based PL BioScience closes Series A for 7.8 million euros - FYB Financial Yearbook","description":"Aachen-based PL BioScience GmbH, a pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing round. The financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/","og_locale":"en_US","og_type":"article","og_title":"Aachen-based PL BioScience closes Series A for 7.8 million euros - FYB Financial Yearbook","og_description":"Aachen-based PL BioScience GmbH, a pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing round. The financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission.","og_url":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2024-08-13T14:11:32+00:00","article_modified_time":"2024-08-18T14:12:05+00:00","og_image":[{"width":1500,"height":1000,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Aachen-based PL BioScience closes Series A for 7.8 million euros","datePublished":"2024-08-13T14:11:32+00:00","dateModified":"2024-08-18T14:12:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/"},"wordCount":790,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg","articleSection":["General","Featured","News","Investors","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/","url":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/","name":"Aachen-based PL BioScience closes Series A for 7.8 million euros - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg","datePublished":"2024-08-13T14:11:32+00:00","dateModified":"2024-08-18T14:12:05+00:00","description":"Aachen-based PL BioScience GmbH, a pioneer in the field of sustainable, animal-free cell culture media, has successfully closed a Series A financing round. The financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/tina-dreimann-betterventures.jpeg","width":1500,"height":1000,"caption":"Tina Dreimann, Gr\u00fcnderin und Gesch\u00e4ftsf\u00fchrerin von better ventures \u00a9 better ventures"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/aachen-based-pl-bioscience-closes-series-a-for-7-8-million-euros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Aachen-based PL BioScience closes Series A for 7.8 million euros"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=52206"}],"version-history":[{"count":1,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52206\/revisions"}],"predecessor-version":[{"id":52208,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52206\/revisions\/52208"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/52204"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=52206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=52206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=52206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}